Table 2 Studies on VEGF antibodies.
Substance | Author(s) | Year | Study type | N | tumour | RT dose/ChTx/technique | Toxicity |
|---|---|---|---|---|---|---|---|
Bevacizumab | Vredenburgh et al. [147] | 2010 | Â | 125 | Glioblastoma | 59,4 Gy/Temozolomide | Grade III Thromboembolic events: 2% |
| Â | Crane et al. [63] | 2009 | Phase II | 82 | Pancreatic Cancer | 50,4 Gy/Capecitabine | Toxicities possibly attributable to bevacizumab: GI bleeding: 6%. (d83,127,179, 180, 316); grade III, IV, V GI perforation: 4%. (d195,231,286) DVT grade III + IV: 4%; grade III hypertension: 2%; |
| Â | Lai et al. [72] | 2010 | Phase II | 70 | Glioblastoma | 60 Gy/Temozolomide | Grade IV cerebrovascular ischemia: 9%; Grade III+IV CNS hemorrhage: 3%; Grade III+IV GI bleeding/perforation 6%; grade IIII Optic neuropathy: 1%. Grade III+IV venous Thrombosis/PE: 19%. |
| Â | Crane et al. [62] | 2006 | Phase I | 48 | Pancreatic Cancer | 50,4 Gy/Capecitabine | Toxicities possibly attributable to bevacizumab: grade III+V ulceration with bleeding in RT field: 8%. (retrospectively fistulous connection identified in 4%) Grade III GI perforation: 4%; bleeding outside field): 4%; grade III hypertension: 2%. |
| Â | Seiwert et al. [148] | 2008 | Phase I | 43 | Head & Neck | 63-72 Gy/5-FU and Hydroxyurea | Grade V bleeding events: 5%; grade V infection/sepsis: 7%, 2% unknown cause of death; grade III+ Thromboembolic events: 5% DVT, 2% stroke (leading to fatal sepsis, see above); fistula (due to radionecrosis or residual tumour): 12%. Tissue necrosis 9%. |
| Â | Spigel et al. [149] | 2009 | Phase II | A 29 B 5 | SCLC | 61,2 Gy/Carboplatin/Irinotecan (A-limited stage B-locally advanced) | A Grade IV+V tracheoesophageal fistula: 7%. Grade V aerodigestive hemorrhage. B Grade III tracheoesophageal fistula: 40%. Both studies closed due to toxicity. |
| Â | Willet et al. [58] | 2009 | Phase II | 32 | Rectal Cancer | 50,4 Gy//5-FU | Grade III toxicities: GI abscess 3%, Hypertension 9%, radiation dermatitis: 6%; wound separation 3%. No grade IV. |
| Â | Dipetrillo et al. [55] | 2012 | Phase I | 26 | Rectal Cancer | 50,4 Gy/FOLFOX | Grade III + IV Diarrhea: 42%; Bleeding (g3): 4%; g3 neuropathy: 4%; Radiation dermatitis G3: 8%; postoperative wound complications: 35%-the study was discontinued due to this toxicity. |
| Â | Crane et al. [53] | 2010 | Phase II | 25 | Rectal Cancer | 50,4 Gy/Capecitabine | grade III perianal desquamation: 4%; 12% major surgical complications such as anastomotic dehiscence (4%), wound dehiscence (8%) |
|  | Gutin et al. [68] | 2009 | Phase I | 25 | Glioblastoma/Anaplastic Gliomas | 30 Gy/5 × 6 Gy | Grade IV Gastrointestinal bleeding: 4%, bowel perforation: 4%, wound healing complication: 4%. Grade III CNS hemorrhage: 4%. |
|  | Koukourakis et al. [59] | 2009 | Phase I/II | 22 | Rectal Cancer | 15 × 3,4 Gy/amifostine, capecitabine | Fistula: 9%, grade IV skin necrosis 5%. |
| Â | Niyazi et al. [69] | 2010 | Retrospective | 20 | Recurrent Glioblastoma | 36 Gy | Grade IV wound healing complication: 5%. grade III DVT: 5%. |
|  | Koukourakis et al. [150] | 2011 | Phase II | 19 | Rectal cancer | 10 × 3, 4 Gy Amifostine/Capecitabine | Grade III diarrhea: 11%. |
| Â | Goyal et al. [65] | 2010 | Retrospective | 14 | Breast cancer | 50 Gy + 10 Gy | No Grade III/IV toxicity (only acute toxicity assessed) |
| Â | Czito et al. [61] | 2007 | Phase I | 11 | Rectal Cancer | 50,4 Gy/Oxaliplatin + Capecitabine | No grade III + toxicities attributable to bevacizumab: grade III-IV diarrhea: 27%, |
| Â | Resch et al. [151] | 2011 | Phase II | 8 | Rectal cancer | 45 Gy/Capecitabine | Discontinued due to tox after 8 Pt., Grade III GI bleeding: 25%, Grade III diarrhea: 25% |
| Â | Kelly et al. [71] | 2010 | Case reports | 3 | Glioblastoma | Â | Optic neuropathy |
| Â | Vargo et al. [152] | 2011 | Case report | 1 | Glioblastoma | Â | Dural venous thrombosis |